{"id":"atazanvir-ritonavir-efavirenz","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hyperbilirubinemia"},{"rate":null,"effect":"CNS effects (efavirenz-related)"}]},"_chembl":{"chemblId":"CHEMBL223228","moleculeType":"Small molecule","molecularWeight":"315.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir is a protease inhibitor that blocks HIV protease, preventing the maturation of viral particles. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, increasing atazanavir levels. Efavirenz is a non-nucleoside reverse transcriptase inhibitor that blocks the enzyme required for HIV RNA conversion to DNA. Together, these three agents target multiple steps in the HIV replication cycle.","oneSentence":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:10.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT00135343","phase":"PHASE3","title":"A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-04","conditions":"HIV Infections","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Reyataz & Sustiva"],"phase":"phase_3","status":"active","brandName":"Atazanvir/ritonavir + efavirenz","genericName":"Atazanvir/ritonavir + efavirenz","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV protease and reverse transcriptase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}